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Objective. This study investigated the susceptibility of 198 clinical isolates of Candida species against caspofungin,
amphotericin B, itraconazole, and fluconazole.
Study Design. Suspensions of the microorganisms were spread on Roswell Park Memorial Institute (RPMI) agar plates. Etest
strips were placed on the plates, and the minimal inhibitory concentration (MIC) was read after incubation (48 h at 37C). Data
were analyzed by a factorial analysis of variance and a 2  2 post hoc test (a ¼ .05).
Results. C glabrata showed the highest MIC values (P < .001) against caspofungin, itraconazole, and fluconazole. For
amphotericin B, the MIC values of C tropicalis and C glabrata (P ¼ .0521) were higher than those of C albicans (P < .001).
Itraconazole was the least effective antifungal; 93.3% of the C glabrata isolates, 3.3% of the C albicans, and 1.3% of the
C tropicalis were resistant. All microorganisms were susceptible to caspofungin and amphotericin B.
Conclusions. Caspofungin and amphotericin B should be recommended as an effective alternative for the management of oral
Candida infections when treatment with topical or other systemic drugs has definitely failed. (Oral Surg Oral Med Oral Pathol
Oral Radiol 2013;116:562-569)Oral candidiasis is an opportunistic infection found in
healthy and medically compromised individuals. The
prevalence of this disease continues to grow, and it is
one of the most common fungal infections.1 The risk
factors for oral candidal infection are complex. Denture
bioﬁlms represent a protective reservoir for oral
microbes,2-5 favoring yeast proliferation, enhancing
their infective potential, and protecting fungal cells
against several medications.6 The exopolymeric matrix
coupled with the organization of layers of cells within
the bioﬁlm may confer protection to organisms in the
inner layers, contributing to antifungal resistance.7
When local factors are associated with the complica-
tions of systemic diseases, such as diabetes mellitus, an
increase in the incidence of oral Candida disorders and
the susceptibility of patients is observed.8 In fact,
a large number of oral Candida species carriers haveThis work was supported by Brazil’s National Council for Scientiﬁc
and Technological Development (CNPq) (grant 501033/2011-4).
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562been reported in patients with diabetes.3,4,8 The oral
candidiasis progression is also often faster and more
severe in patients with diabetes, because their immune
systems are often deﬁcient enough to predispose to
Candida colonization and other oral diseases.9,10 Other
predisposing factors modulate individual risk of infec-
tions in patients with diabetes. The salivary glucose
levels found in patients with diabetes favors yeast
growth due to increased number of available receptors
for Candida.9 Consequently, buccal cells from these
patients have shown a greater adherence to Candida
yeasts.11,12 Their reduced salivary ﬂow rate10 also
promotes the oral carriage of Candida.
The emergence of antifungal resistance among
Candida species isolates is another factor that can
contribute to Candida infections. Clinically, antifungal
resistance is deﬁned as persistence or progression of an
infection despite appropriate antimicrobial therapy.13
Copious references in the literature have beenmade to the
development of resistant yeasts,14-24 which could beStatement of Clinical Relevance
These ﬁndings conﬁrm the resistant susceptibility
proﬁle of C glabrata isolates against azole antifun-
gals, especially itraconazole, in persons with dia-
betes and denture stomatitis. Thus, surveillance of
antifungal susceptibility can be helpful in deter-
mining optimal therapeutic approaches for these
individuals.
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especially azoles. According to Goldman et al.,19 resis-
tance among Candida yeasts can be associated with
genetic mutation. The authors identiﬁed 18 mutations
in ﬂuconazole-resistant isolates of C albicans from
patients with acquired immunodeﬁciency syndrome
(AIDS).19 Other authors20,22 found that exposure to
antifungal agents provided a positive selection pressure
for non-albicans yeasts, described as the replacement of
ﬂuconazole-susceptible C albicans strains with other
species, for example C glabrata, C krusei, and C dub-
liniensis. There are also species that are considered
intrinsically less sensitive,13 such as C glabrata and C
krusei. Regardless of the mechanism of Candida resis-
tance, studies have found differences in the susceptibility
against several drugs that were dependent on theCandida
species involved in the infection and the underlying
disease.14-17,20,21,23 In general, non-albicans Candida
species are less susceptible to antifungals than is
C albicans.17,20,23 In addition, it was found that clinical
isolates of Candida from patients with human immuno-
deﬁciency virus (HIV)16,20 and from patients with dia-
betes14,15 have a higher resistance to antifungals than do
isolates from individuals without systemic complica-
tions. This resistance has important clinical implications,
because the non-albicans Candida species have been
isolated with increasing frequency from patients with
Candida-associated denture stomatitis,2,5 including those
with diabetes.3,4,8 Moreover, it may be related to the
failure of therapies,16,24 recurrence of infections,18 and
higher levels of mortality.21
Currently, oral candidiasis is commonly treated by
means of topical or systemic approaches. The most
common antifungal drugs are polyenes (amphotericin B
and nystatin) and azoles (ﬂuconazole and itraconazole).1
More recently, a new class of antifungals, the echino-
candins (such as caspofungin),25 has been found to
eliminate Candida species.26,27 The increasing number
of clinical isolates resistant to these antifungal therapies
highlights the need for antifungal susceptibility testing to
monitor the antifungal resistance of these microorgan-
isms. As pathogenicity and antifungal susceptibility vary
among strains, an accurate identiﬁcation of the suscep-
tibility proﬁle of the disease-causing strain of Candida
could guide the therapeutic choice and the clinical
treatment. In addition, an accurate identiﬁcation of strains
isolated from infections in patients with diabetes is
especially important, because these patients are more
likely to carry species other than C albicans,8 which may
be less sensitive to antifungal agents. Although there
have been numerous studies14-24 evaluating the suscep-
tibility proﬁle of Candida species against various drugs,
there have been only a few that evaluated the suscepti-
bility of clinical isolates obtained from the denture bio-
ﬁlms of healthy subjects28,29 or the oral cavity of patientswith diabetes.14,15,30 In addition, to the authors’ knowl-
edge, this is the ﬁrst study that evaluated the suscepti-
bility of clinical isolates obtained from the denture
bioﬁlm of patients meeting speciﬁc criteria for type 2
diabetes and Candida-associated denture stomatitis.
Thus, the aim of the present study was to characterize the
susceptibility proﬁle of a Brazilian stock collection of
198 clinical isolates of oral Candida species. In addition,
this study aimed to compare the susceptibility of clinical
isolates of Candida among different sources: healthy
subjects and subjects with Candida-associated denture
stomatitis with or without diabetes.
MATERIALS AND METHODS
Clinical isolates of Candida
This study was conducted with 198 clinical isolates of
Candida obtained from the yeast stock collection of
the Laboratory of Applied Microbiology (Laboratório
de Microbiologia Aplicada) at Universidade Estadual
Paulista (UNESP) in Araraquara, São Paulo, Brazil.
These isolates were previously obtained from the bio-
ﬁlm of the tissue surfaces of the dentures of edentu-
lous patients with various systemic or oral conditions.
Seventy-four clinical isolates were obtained from healthy
subjects who were not diabetic and had no clinical signs
of Candida-associated denture stomatitis31; 82 clinical
isolates were obtained from subjects with Candida-
associated denture stomatitis who were not diabetic2,5;
and 42 clinical isolates were obtained from patients with
diabetes and Candida-associated denture stomatitis.4 All
procedures followed the criteria of Resolution 196/96
of the Brazilian Health Ministry, and the study was
approved by the Ethics Committee of the Araraquara
Dental School, UNESP.
The yeast identiﬁcation procedures for Candida
species included the presumptive identiﬁcation on
CHROMAgar Candida (CHROMAgar, Paris, France),
the micromorphologic characteristics on corn meal agar
with polysorbate 80 (Tween 80, Sigma-Aldrich Co
LLC, St Louis, MO, USA) for the production of hyphae
and chlamydoconidia, and the assimilation of a variety
of carbon and nitrogen sources using the ID32C yeast
identiﬁcation system (bioMérieux SA, Marcy-l’Étoile,
France).2,4,5,31 In addition, the hypertonic Sabouraud
broth test32 was performed to discriminate C albicans
and C dubliniensis. In general, 148 isolates were
identiﬁed as C albicans, 30 as C glabrata, and 20 as
C tropicalis. Four reference strains were used as the
controls: C albicans ATCC 90028 (ATCC, Manassas,
VA, USA), C albicans wild-type strain SC 5314,
C glabrata ATCC 2001, and C tropicalis ATCC 4563.
All isolates were maintained in a yeast-peptone-glucose
medium (1% yeast extract, 2% Bacto Peptone [Becton
Dickinson, Franklin Lakes, NJ, USA], and 2%
D-glucose with 2% agar) and frozen at 70C until use.
Table I. Interpretive breakpoints of MIC adopted in the
present study
Antifungal
Breakpoint
Susceptible
Susceptibleedose
dependent Resistant
Caspofungin 2 mg/mL Not applicable >2 mg/mL
Amphotericin B 1 mg/mL Not applicable >1 mg/mL
Itraconazole 0.125
mg/mL
0.25 mg/mL  MIC
 0.5 mg/mL
1 mg/mL
Fluconazole 8 mg/mL 16 mg/mL  MIC
 32 mg/mL
64 mg/mL
MIC, minimal inhibitory concentration.
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The microorganisms were subcultured onto Sabouraud
dextrose agar (Acumedia Manufactures Inc, Baltimore,
MD, USA) plates supplemented with chloramphenicol
(0.05 g/L) and incubated at 37C for 24 to 48 hours. To
prepare the yeast inoculums, a loopful of the agar stock
cultures was transferred to 5 mL of yeast nitrogen base
broth (BD Difco; Becton Dickinson) supplemented
with 100mM glucose and incubated at 37C overnight
in an orbital shaker (75 rpm). Cells of the resul-
tant cultures were harvested and washed twice with
phosphate-buffered saline (pH 7.2) at 5000  g for
5 minutes. Washed microorganisms were resuspended
in sterile saline solution and spectrophotometrically
standardized at an optical density of 520 nm (Bio-
spectro, Equipar Ltda, Curitiba, Paraná, Brazil) to
a ﬁnal concentration of 106 cells/mL.23Antifungal susceptibility test
Candida species strains were analyzed with regard to
their susceptibility to 4 antifungal agents based on the
minimal inhibitory concentration (MIC) in the Etest
(bioMérieux SA). The following drugs and their
respective minimum and maximum concentrations were
used: caspofungin (CS) (concentration range, 0.002 to
32 mg/mL), amphotericin B (AP) (0.002 to 32 mg/mL),
itraconazole (IT) (0.002 to 32 mg/mL), and ﬂuconazole
(FLU) (0.016 to 256 mg/mL).
For the assays, Roswell Park Memorial Institute
(RPMI) agar supplemented with 2% glucose was used as
the test medium. An RPMI medium (Sigma-Aldrich Co
LLC) was prepared using 10.4 g of RPMI, 38.16 g of
MOPS 0.165M (3-(N-Morpholino)propanesulfonic
acid), and 20 g of glucose in 1 L of distilled water. The
pH of this solution was adjusted to 7.0 and it was ster-
ilized by ﬁltration in a 0.22 mm membrane. The agar
medium was prepared using 18 g of agar in 1 L of
distilled water. This solution was autoclaved, cooled
down to 50C, and added to the RPMI medium. The
yeast suspensions of 106 cells/mL23 were spread
uniformly on RPMI agar plates with sterile swabs and
allowed to dry for 15 minutes. Thereafter, the Etest strips
containing CS, AP, IT, and FLU were placed on the
inoculated plates with sterile forceps. The plates were
incubated for 48 hours at 37C, after which the MICs
were read as the lowest concentration at which the border
of the elliptical inhibition zone of growth intercepted the
scale on the Etest strip. For the MIC values that yielded
results falling in between conventional serial 2-fold
dilution, the next highest dilution was assigned.27Category MIC breakpoints
MIC interpretive criteria for CS, FLU, and IT were
applied according to the Clinical and LaboratoryStandards Institute (CLSI) document M27-A3.33 For
AP, the interpretive breakpoints proposed in the liter-
ature23,24 were used, because the CLSI has not yet
established these values. The MIC breakpoints of each
antifungal for susceptible, susceptibleedose dependent,
and resistant isolates are described in Table I.Statistical analysis
The variable of interest in the present study was the
MIC value of the clinical isolates expressed in micro-
grams per milliliter (mg/mL). The factors analyzed were
the different antifungals tested (CS, AP, IT, and FLU);
the 3 Candida species (C albicans, C glabrata, and
C tropicalis); and the sources of the isolates of
Candida. The latter were clinical isolates from subjects
without diabetes and without clinical signs of Candida-
associated denture stomatitis (healthy subjects); sub-
jects without diabetes and with Candida-associated
denture stomatitis; and subjects with both diabetes
and Candida-associated denture stomatitis. Data were
transformed with the arc tangent function so that the
assumptions of normality and homogeneity of variance
were satisﬁed. Then, a factorial analysis of variance was
used, and the signiﬁcant differences were explored by
a series of 2  2 comparisons to test the post hoc
hypotheses of interest (a ¼ .05).
RESULTS
Table II provides the descriptive statistics of the
susceptibility proﬁles of all clinical isolates evaluated in
the present study. All clinical isolates were susceptible
to CS and AP, regardless of the Candida species and
sources. The MIC values for CS ranged from 0.002 to
0.125 mg/mL for C albicans, from 0.002 to 0.25 mg/mL
for C glabrata, and from 0.002 to 0.064 mg/mL for
C tropicalis strains. For AP, the MIC values ranged
from 0.002 to 0.25 mg/mL for C albicans and from
0.047 to 0.38 mg/mL for both the C glabrata and
C tropicalis strains. In general, 3.4% of the clinical
isolates of C albicans (5/148) and 5% of those of
C tropicalis (1/20) were resistant to IT, with MIC
Table II. Number of resistant, susceptibleedose
dependent, and susceptible clinical isolates for each
antifungal tested
Antifungal
C albicans
(n ¼ 148)
C glabrata
(n ¼ 30)
C tropicalis
(n ¼ 20)
R S-DD S R S-DD S R S-DD S
Caspofungin 0 0 148 0 0 30 0 0 20
Amphotericin B 0 0 148 0 0 30 0 0 20
Itraconazole 5 2 141 28 2 0 1 8 11
Fluconazole 0 5 143 0 18 12 0 0 20
C, Candida; R, resistant; S-DD, susceptibleedose dependent; S,
susceptible.
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strains and 1 mg/mL for the C tropicalis strain. None of
the 30 clinical isolates of C glabrata were susceptible to
IT, and the MIC values ranged from 1 to 32 mg/mL.
Considering the FLU susceptibility proﬁle, resistance
was not found among any clinical isolate. However, it
was found that 3.4% of the clinical isolates of C albi-
cans (5/148) and 60% of those of C glabrata (18/30)
were susceptibleedose dependent to this medication,
with MIC values ranging from 12 to 32 mg/mL and 16
to 48 mg/mL, respectively. The highest FLU MIC value
of the C tropicalis strains was 4 mg/mL. Considering
the control strains, isolates from all species were
susceptible to all antifungals tested, with the exception
of C glabrata ATCC 2001, which were resistant to IT.
A representative image of the RPMI agar plate is shown
in Figure 1.
Factorial analysis of variance (Table III) found that
the effect of the antifungal and its interaction with
Candida species on the MIC values was signiﬁcant
(P < .0001). There was no further statistical signiﬁ-
cance for the clinical sources of the isolates, Candida
species, and their interaction (P > .05).
The 2  2 post hoc comparison test (Table IV) found
that, for CS, IT, and FLU, the MIC values of C glabrata
were the highest (P < .001). For CS and FLU, there
were no signiﬁcant differences between the MIC values
of C albicans and C tropicalis (P ¼ .106). For IT, the
C tropicalis strains showed the lowest MIC values (P <
.001). For AP, there was no signiﬁcant difference
between the MIC values of C tropicalis and C glabrata
(P ¼ .0521), which were higher than that of C albicans
(P < .001).DISCUSSION
In the present study, 4 antifungal agents were evaluated:
2 azole derivatives, a polyene, and an echinocandin.
Considering the azoles, FLU and IT were tested
because they are widely used for the treatment of
several fungal infections, including oral candidiasis.1,35
Among all the antifungals tested, IT was the leasteffective, especially against C glabrata. We found that
5 isolates of C albicans (3.4%), one of C tropicalis
(5%), and 28 of C glabrata (93.3%) were resistant to
this azole. An in vitro study28 also evaluated the
susceptibility proﬁles of the clinical isolates of Candida
from patients with denture stomatitis and found similar
results: 5.9% of the isolates of C albicans, 11.1% of
those of C tropicalis, and 33.3% of those of C glabrata
were resistant to IT. The frequency of resistance against
this azole seems to be increasing, and there are many
reports of oral infections caused by resistant strains of
non-albicans species of Candida.28,36-38 Despite the
low resistance of C albicans isolates, the synergic
relationship that exists between the Candida species
can favor the colonization of more resistant strains,
enhancing the infection process and the severity of the
disease. A recent study39 evaluated the synergistic
infection of a reconstituted human oral epithelium by
C albicans and C glabrata and revealed that C albicans
promoted the invasiveness of C glabrata. The authors
suggested that the damage to the integrity of the
epithelial surface caused by the growing tips of the
C albicans hyphae provided access to lower epithelial
layers for C glabrata yeast by the vacuolized tissue
portions.39 This ﬁnding may be supported by clinical
studies that have found a coinfection of C albicans with
C glabrata, C tropicalis, or both in oral fungal infec-
tions.2-5,40 Also, some of these in vivo studies found
that both C tropicalis3 and C glabrata40 were associ-
ated with more severe oral infections. Therefore, we
may wonder whether this synergic relationship may be
responsible for the persistent and recurrent infections
when resistant isolates, such as those found here, are
involved. C tropicalis and C glabrata have the ability
to cause fungemia in humans and are associated with
a higher mortality rate than is C albicans.41,42 Thus, the
effect that the resistance of the non-albicans isolates,
especially those of C glabrata, may have in the treat-
ment of these infections has to be highlighted. In the
present study, the C glabrata clinical isolates had the
highest MIC values for all the antifungals tested.
Despite the results reported for the IT susceptibility
among the clinical isolates, the ﬁndings showed that all
isolates were susceptible to FLU. Other studies also
investigated clinical isolates from oral candidiasis
patients and failed to ﬁnd Candida species resistance
against FLU.28,29,43 Differences in the in vitro suscep-
tibility to FLU have been reported in the literature,
ranging from 70% to 100% of oral isolates, depending
on the groups of patients studied.14,15,28,29,36-38,43,44 In
fact, higher levels of resistance have been reported for
Candida isolates from immunocompromised patients,
such as those who are HIV positive36,38 or who have
advanced cancer.37 We found that 3.4% of the C albi-
cans and 60% of the C glabrata isolates were
Table IV. Mean MIC values for the three Candida
species, regardless of the clinical source
Candida
species
Antifungal
Caspofungin Amphotericin B Itraconazole Fluconazole
C albicans 0.029A 0.125A 0.898A 0.904A
C glabrata 0.066B 0.228B 10.383B 17.267B
C tropicalis 0.024A 0.171B 0.306C 0.811A
MIC, minimal inhibitory concentration.
A,B,CIn columns, values with the same superscript letters were not
statistically different (P > .05).
Fig. 1. Representative image of a clinical isolate of Candida albicans, which was resistant to itraconazole (a; minimal inhibitory
concentration, 32 mg/mL) and susceptible to amphotericin B (b; minimal inhibitory concentration, 0.25 mg/mL).
Table III. Factorial analysis of variance for the trans-
formed MIC values
Factors SQ DF F P
Intercept 1.39 1 42.56 .0000
Candida species 0.13 2 2.02 .1338
Antifungal 2.16 3 22.04 <.0001*
Source of clinical isolate 0.11 2 1.73 .1773
Candida species  antifungal 13.11 6 66.94 <.0001*
Candida species  source 0.09 4 0.71 .5834
Antifungal  source 0.36 6 1.85 .0872
Candida species 
antifungal  source
0.42 12 1.08 .3726
Residual 24.68 756
MIC, minimal inhibitory concentration; F, F-Statistics; SQ, sum of
squares; DF, degrees of freedom.
*Signiﬁcant difference, P < .05.
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in accordance with the literature.15,28,37 Because of its
high cost, FLU has been used infrequently in Brazil,
and this may have accounted for the elevated suscep-
tibility of the clinical isolates observed here. The
mechanism of action of azole derivatives such as IT and
FLU is based on the inhibition of the synthesis of
ergosterol,45,46 a major constituent of the fungal cell
membrane. In addition, the exposure to azole antifungal
agents reduced candidal adhesion to the buccal
epithelial cells47-49 and denture acrylic surfaces.50
Another surprising mode of interaction between FLU
and the Candida isolates is the fact that this drug
decreased the production of phospholipase, an enzyme
that plays an important role in the tissue invasion
process and, consequently, in the pathogenicity of
Candida species.49
In addition to azoles, the polyenes and echino-
candins, represented by AP and CS, respectively, were
evaluated. The results showed that all of the 198 clinical
isolates of Candida species were susceptible to AP andCS, regardless of the Candida species and clinical
sources. The polyene AP has been widely used for the
treatment of oral and disseminated candidiasis,1,45,46,51
and Candida resistance is rare. As observed in the
present study, several investigations found that the
clinical isolates of various Candida species (obtained
from blood cultures of hospitalized patients23,27,34;
from oral cultures of patients with diabetes melli-
tus,14,15 AIDS,38 and denture stomatitis28; and from oral
cultures of patients wearing orthodontic appliances44)
were susceptible to AP. In fact, resistance has been only
sporadically described in oral isolates from children
with HIV36 and from patients with advanced cancer,37
indicating the broad-spectrum activity of this drug
against Candida isolates, even in immunocompromised
individuals. The high efﬁcacy of the polyenes is related
to their mechanism of action. Rather than inhibiting
ergosterol synthesis, AP interacts with ergosterol and
causes membrane leakage, resulting in cell death.45,46
AP is considered the gold standard for the treatment of
invasive fungal infections. However, this polyene has
a limited clinical application because of its severe renal
toxicity45,46 and the lack of a preparation for topical
use.36 In addition, the tolerability of the oral-rinse AP
product has been found to be limited, resulting in
noncompliance.51
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study were also susceptible to CS. In agreement with
our results, there are some reports in the literature that
found that this drug had efﬁcacy against ﬂuconazole-
resistant Candida26 and to several clinical isolates,
including C albicans, C tropicalis, C glabrata, and
C krusei.27 In addition, clinical studies found that this
echinocandin was effective for the treatment of esoph-
ageal and invasive candidiasis,52,53 including in patients
who were HIV positive.54 However, contrasting results
have also been reported. In an epidemiologic study
from 100 blood isolates of Candida collected from
candidemia patients, Motta et al.27 found 2 C para-
psilosis strains resistant to this drug. Pfaller et al.55
evaluated 5346 Candida species isolates and found
a susceptibility rate of 99% to CS. It is important to
mention that, although it is expensive, CS is well
tolerated by patients and has few drug-drug interac-
tions.53 It may be worth noting that both CS and lipid
formulations of AP have also been found to be active
against Candida bioﬁlms.56 The mode of action of
echinocandins is based on the selective inhibition of the
synthesis of glucan, an essential component of the
fungal cell wall.46 Moreover, CS has been found to
reduce the adhesion of Candida species to human cells
by about 40% to 90%, depending on the time of
exposure and drug concentration.57 This alternative
mechanism of action was also observed for AP, which
reduced the ability of oral C albicans isolates to adhere
to denture acrylic surfaces.50 Considering the impor-
tance of Candida adhesion to buccal cells and denture
surfaces during the infectious process, this is another
relevant mechanism of action of these medications.
In the present study, the clinical sources of the
isolates had no effect on the MIC values obtained for all
antifungals tested. No signiﬁcant differences in MIC
values were found among the clinical isolates obtained
from healthy denture wearers and those with oral
candidiasis with or without diabetes. This ﬁnding is in
agreement with previous data, in which Candida strains
isolated from healthy patients and from patients with
oral candidiasis had an identical susceptibility
proﬁle.29,43 In those studies comparing the suscepti-
bility proﬁles in subjects with and without diabetes,
conﬂicting results were obtained. Although Manfredi
et al.30 found no differences in antifungal susceptibility
between the Candida isolates from diabetic and
nondiabetic subjects, Al-Attas et al.14 and Bremenkamp
et al.15 found that isolates from subjects with diabetes
had higher rates of resistance to ﬂucytosine, ﬂucona-
zole, ketoconazole, miconazole, and econazole than did
those from healthy controls. It is important to mention
that this variability may be related to the drugs tested. In
these latter studies in patients with diabetes, AP and CS
were not evaluated. Another reason for the variabilitymay be the methods used in the investigations. The
classical microdilution method described in the CLSI
M27-A3 standard33 is widely used6,15,21,34,37,43 and is
still considered the gold standard for susceptibility tests.
Nevertheless, in addition to being laborious and time-
consuming, the method seems not to be the most
sensitive and reliable for detecting resistance against
some antifungals, such as AP.34 To overcome these
limitations, a number of rapid and easy-to-use com-
mercial products have been proposed to test antifungal
susceptibility, such as Fungitest,30 disk diffusion
test,21,44 and Etest.6,17,23,27,29,36,37,43,44 In the present
investigation, the Etest kit was used because it is a cost-
effective, simple, accurate, reliable, and precise method
that has had an excellent agreement with other tests,
such as the microdilution21,58 and disk diffusion
assays.59
The widespread use of systemic antifungal agents for
both treatment and prophylactic purposes has resulted in
an increase in antifungal resistance and in a noticeable
shift toward Candida species other than C albicans with
higher resistance, as observed by the present study. The
resistance of Candida isolates to currently available
antifungals is a relevant factor because it may have
implications for morbidity and mortality. A prospective
study found higher mortality rates in patients infected
with ﬂuconazole resistant Candida yeasts when
compared with those infected with ﬂuconazole suscep-
tible yeasts (19.0% and 8.6%, respectively).21 With this
in mind, in vitro susceptibility tests can be highly rele-
vant for the patients who do not respond to conventional
antifungal treatments. The great advantage of the tests,
including the Etest, is that they can allow a quick answer
regarding Candida resistance to antifungals, guiding
clinicians in selecting the most appropriate anti-Candida
agent and preventing drug misuse. In addition, the
association of an in vitro susceptibility test with the
clinical use of an antifungal agent may contribute to
a more effective treatment of candidiasis. In the present
study, all clinical isolates were susceptible to CS and AP.
Although these medications are not the ﬁrst choice in
treating patients with Candida-associated denture
stomatitis, they can be an effective alternative if topical
or other systemic drugs have deﬁnitely failed.REFERENCES
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